​

AIxCrypto Holdings Stock (NASDAQ:AIXC)


OwnershipChartTranscripts

Previous Close

$1.13

52W Range

$0.59 - $5.97

50D Avg

$0.97

200D Avg

$1.31

Market Cap

$27.72M

Avg Vol (3M)

$1.94M

Beta

0.57

Div Yield

-

AIXC Company Profile


AIxCrypto Holdings, Inc. is a clinical-stage biopharmaceutical company committed to discovering and developing innovative treatments for both adult and pediatric oncology. Its leading investigational therapeutic, QN-302, is a small molecule G-quadruplexes (G4)-selective transcription inhibitor currently progressing through Phase I clinical trials for pancreatic cancer and a range of other solid tumors. The firm is also advancing Pan-RAS, a preclinical-stage program targeting advanced solid tumors. Founded in 1996 and headquartered in Carlsbad, California, the company rebranded from Qualigen Therapeutics, Inc. to AIxCrypto Holdings, Inc. in November 2025.

Show More

Industry

Software - Infrastructure

Sector

Technology

Exchange

NASDAQ

ADR

-

Country

US

Employees

10

IPO Date

Jun 23, 2015

Website

AIXC Performance


Latest Earnings Call Transcripts


Q3 26Nov 12, 26 | 7:00 PM
Q2 26Aug 07, 26 | 7:30 PM
Q1 21Aug 18, 20 | 4:30 PM

Peer Comparison


TickerCompany
ATGLAlpha Technology Group Limited
IMXIInternational Money Express, Inc.
OLBThe OLB Group, Inc.
JGAurora Mobile Limited
AUIDauthID Inc.
CWDCaliberCos Inc.
CTORCitius Oncology, Inc.